Struma ovarii (SO) is a highly specialized ovarian teratoma, consisting of thyroid tissue. Rarely, carcinomas histologically identical to their thyroid counterparts may occur, and are comprehensively defined as malignant struma ovarii (MSO). Their optimal management is controversial, and the molecular profile of the malignant counterpart in the ovary is incompletely known. In this study, the clinicopathological and molecular features of six MSO from different Italian Institutions were analysed, to explore genetic profiles of potential therapeutic interest.
The histopathological features and immunoprofile (according to the known markers Galectin-3, HBME1, cytokeratin 19 and CD56) were reviewed. In addition, all cases underwent genetic analysis with a next-generation sequencing (NGS) hot spot cancer panel detecting mutations in 50 genes involved in cancerogenesis. RET/PTC rearrangements and TERT promoter alterations were also evaluated.
Papillary carcinoma in all similar to its thyroid counterpart was found in five of six cases, including classical (two tumors) and follicular variant (three tumors) types. The last case was a poorly differentiated carcinoma. An activating gene mutation, was detected in five of six cases, including two NRAS, two BRAF, and one JAK3 oncogene mutations. No alterations were found in the other panel genes, nor in TERT promoter, or in RET chromosomal regions.
MSO is a rare condition. Papillary carcinoma is the predominant malignant type, sharing both histomorphological and molecular features of its thyroid counterpart. Interestingly, the single case of poorly differentiated carcinoma displayed a JAK3 mutation. The presence of such driving mutation could be of potential interest in guiding postoperative treatment.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
M. Russo, I. Marturano, R. Masucci, M. Caruso, M.C. Fornito, D. Tumino, M. Tavarelli, S. Squatrito, G. Pellegriti, Metastatic malignant struma ovarii with coexistence of Hashimoto’s thyroiditis. Endocrinol. Diabetes Metab. Case Rep. 2016, 160030 (2016)
K. Khatchapuridze, N. Kekelidze, Z. Tsitsishvili, M. Mchedlishvili, D. Kordzaia, Papillary thyroid carcinoma in struma ovarii. Gynecol. Endocrinol. 11, 1–4 (2020)
M.R. Siegel, R.J. Wolsky, E.A. Alvarez, B.M. Mengesh, Struma ovarii with atypical features ans synchromous primary thyroid cancer: a case report and review of the literature. Arch. Gynecol. Obstet. 300, 1693–1707 (2019)
S. Wei, Z.W. Baloch, V.A. LiVolsi, Pathology of struma ovarii: a report of 96 cases. Endocr. Pathol. 26(4), 342–348 (2015)
R. Celestino, J. Magalhães, P. Castro, M. Triller, J. Vinagre, P. Soares, M. Sobrinho-Simões, A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations. Histopathology 55(4), 482–487 (2009)
C. Gobitti, A. Sindoni, C. Bampo, T. Baresic, G. Giorda, L. Alessandrini, V. Canzonieri, G. Franchin, E. Borsatti, Malignant struma ovarii harboring a unique NRAS mutation: case report and review of the literature. Hormones 16(3), 322–327 (2017)
C. Coyne, Y.E. Nikiforov, RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. Endocr. Pathol. 21(2), 144–147 (2010)
B. Stanojevic, R. Dzodic, V. Saenko, Z. Milovanovic, V. Krstevski, P. Radlovic, M. Buta, B. Rulic, L. Todorovic, B. Dimitrijevic, S. Yamashita, Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. BMC Cancer 12, 224 (2012)
J. Schmidt, V. Derr, M.C. Heinrich, C.P. Crum, J.A. Fletcher, C.L. Corless, V. Nosé, BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am. J. Surg. Pathol. 31(9), 1337–1343 (2007)
R. Flavin, BRAFT1799A mutation occurring in a case of malignant struma ovarii. Int. J. Surg. Pathol 15(2), 116–120 (2007)
E.R. Wolff, M. Hughes, M.J. Merino, J.C. Reynolds, J.L. Davis, C.S. Cochran, F.S. Celi, Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. Thyroid 20(9), 981–987 (2010)
A. Gonet, R. Ślusarczyk, D. Gąsior-Perczak, A. Kowalik, J. Kopczyński, A. Kowalska,, Papillary thyroid cancer in a struma ovarii in a 17-year-old nulliparous patient: a case report. Diagnostics. 10(1), 4 (2020)
K.J. Rhoden, C. Johnson, G. Brandao, J.G. Howe, B.R. Smith, G. Tallini, Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab. Investig. 84, 1557–1570 (2004)
Y.E. Nikiforov, J.M. Rowland, K.E. Bove, H. Monforte-Munoz, J.A. Fagin, Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57, 1690–1694 (1997)
M.J. Park, M.A. Kim, M.K. Shin, H.S. Min, Follicular proliferative lesion arising in struma ovarii. J. Pathol. Transl. Med 49(3), 262–266 (2015)
Z. Ting, C. Pingping, G. Yuping, Struma ovarii: a mini review. Int. J. Clin. Exp. Med. 11(10), 10364–10371 (2018)
M.L. Gild, L. Heath, J.Y. Paik, R.J. Clifton-Bligh, B.G. Robinson, Malignant struma ovarii with a robust response to radioactive iodine. Endocrinol. Diabetes Metab. Case Rep 2020, 19–0130 (2020)
A. Tan, C.J. Stewart, K.L. Garrett, M. Rye, P.A. Cohen, Novel BRAF and KRAS mutations in papillary thyroid carcinoma arising in struma ovarii. Endocr. Pathol 26(4), 296–301 (2015)
N.G. Rosenblum, V.A. LiVolsi, P.R. Edmonds, J.J. Mikuta, Malignant struma ovarii. Gynecol. Oncol. 32(2), 224–227 (1989)
R.B. Dardik, M. Dardik, W. Westra, F.J. Montz, Malignant struma ovarii: two case reports and a review of the literature. Gynecol. Oncol. 73(3), 447–451 (1999)
X.A.C. Zhang, Thyroid-type carcinoma of struma ovarii. Arch Pathol. Lab. Med. 134(5), 786–791 (2010)
S.J. Robboy, R. Shaco-Levy, R.Y. Peng, M.J. Snyder, J. Donahue, R.C. Bentley, S. Bean, H.R. Krigman, L.M. Roth, R.H. Young, Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int. J. Gynecol. Pathol. 28(5), 405–422 (2009)
L. Yassa, P. Sadow, E. Marqusee, Malignant struma ovarii. Nat. Clin. Pract. Endocrinol. Metab. 4(8), 469–472 (2008)
C.J. Gomes-Lima, Y.E. Nikiforov, W. Lee, K.D. Burman, Synchronous independent papillary thyroid carcinomas in struma ovarii and the thyroid gland with different RAS mutations. J. Endocr. Soc 2(8), 944–948 (2018). 2018
D. Ma, N.V. Guseva, L. Dahmoush, R.A. Robinson, Struma ovarii with malignant transformation and germline KIT mutation: a case report with review of the literature. Int. J. Gynecol. Pathol 35(5), 442–447 (2016)
M. Yamashita, T. Ishii, S. Ohtori, Y. Oikawa, T. Watanabe, T. Ito, M. Furuya, K. Takahashi, Metastasis of malignant struma ovarii to the lumbar spine. J. Clin. Neurosci. 17(2), 269–272 (2010)
H.G. Vuong, A.M.A. Altibi, U.N.P. Duong, L. Hassell, Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—a meta-analysis. Clin. Endocrinol. 87(5), 411–417 (2017)
R.C. Smallridge, A.M. Chindris, Y.W. Asmann, J.D. Casler, D.J. Serie, H.V. Reddi, K.W. Cradic, M. Rivera, S.K. Grebe, B.M. Necela, N.L. Eberhardt, J.M. Carr, B. McIver, J.A. Copland, E.A. Thompson, RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 99, E338–E347 (2014)
K. Kim, S. Jeon, T.M. Kim, C.K. Jung, Immune gene signature delineates a subclass of papillary thyroid cancer with unfavorable clinical outcomes. Cancers 10(12), 494 (2018)
C. Lebreton, A. Al Ghuzlan, M. Kind, S. Leboulleux, Y. Godbert, Thyroid carcinoma on struma ovarii: diagnosis and treatment. Bull. Cancer 105, 281–289 (2018)
A. Bouchekioua, L. Scourzic, O. de Wever, Y. Zhang, P. Cervera, A. Aline-Fardin, T. Mercher, P. Gaulard, R. Nyga, D. Jeziorowska, L. Douay, W. Vainchenker, F. Louache, C. Gespach, E. Solary, P. Coppo, JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 28(2), 338–348 (2014)
S.D. Li, M. Ma, H. Li, A. Waluszko, T. Sidorenko, E.E. Schadt, D.Y. Zhang, R. Chen, F. Ye, Cancer gene profiling in non-small cell lung cancer reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Med. 9, 89 (2017)
M. Swierniak, A. Pfeifer, T. Stokowy, D. Rusinek, M. Chekan, D. Lange, J. Krajewska, M. Oczko-Wojciechowska, A. Czarniecka, M. Jarzab, B. Jarzab, B. Wojtas, Somatic mutation profiling of follicular thyroid cancer by next generation sequencing. Mol. Cell. Endocrinol. 433, 130–137 (2016)
M. Borowczyk, E. Szczepanek-Parulska, S. Dębicki, B. Budny, F.A. Verburg, D. Filipowicz, B. Więckowska, M. Janicka-Jedyńska, L. Gil, K. Ziemnicka, M. Ruchala, Differences in mutational profile between follicular thyroid carcinoma and follicular thyroid adenoma identified using next generation sequencing. Int. J. Mol. Sci 20(13), 3126 (2019)
C. Molnár, E.S. Bádon, A. Mokánszki, A. Mónus, L. Beke, F. Győry, E. Nagy, G. Méhes, High genetic diversity and no evidence of clonal relation in synchronous thyroid carcinomas associated with Hashimoto’s thyroiditis: a next-generation sequencing analysis. Diagnostics 10(1), 48 (2020)
C. Yin, C. Sandoval, G.H. Baeg, Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia. Leuk. Lymphoma 56(5), 1502–1506 (2015)
T. Tsukada, H. Yoshida, I. Mitsuya, Y. Asami, K. Shiraishi, Malignant struma ovarii presenting with follicular carcinoma: a case report with molecular analysis. Gyneco. Oncol. Rep 30, 100498 (2019)
R. Elisei, C. Romei, M.G. Castagna, S. Lisi, A. Vivaldi, P. Faviana, M. Marinò, C. Ceccarelli, F. Pacini, A. Pinchera,, RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration. Thyroid 145(12), 1355–1361 (2005)
O. Boutross-Tadross, R. Saleh, S.L. Asa, Follicular variant papillary thyroid carcinoma arising in struma ovarii. Endocr. Pathol. 18(3), 182–186 (2007)
A. Leong, P.J.R. Roche, M. Paliouras, L. Rochon, M. Trifiro, M. Tamilia, Coexistence of malignant struma ovarii and cervical papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 98(12), 4599–4605 (2013)
J.L. Marti, V.E. Clark, H. Harper, D.C. Chhieng, J.A. Sosa, S.A. Roman, Optimal surgical management of well-differentiated thyroid cancer arising in struma ovarii: a series of 4 patients and a review of 53 reported cases. Thyroid 22(4), 400–406 (2012)
E. Monti, L. Mortara, S. Zupo, M. Dono, F. Minuto, M. Truini, M. Naseri, M. Giusti, Papillary thyroid cancer in a struma ovarii: a report of a rare case. Hormones 14(1), 159–159 (2015)
Dr. Stefano Rosso and Dr. Roberto Zanetti of CPO and the Piedmont Cancer Registry, Turin, are acknowledged for providing some follow-up information. The authors would also like to thank Dr. Roberto Jura, former Head of Biella Hospital Gynaecology Department for his helpful collaboration.
This study was supported by Fondazione Cassa di Risparmio di Torino (CRT), grant no. 2016.2726, to the Molecular Oncology laboratory of « Edo ed Elvo Tempia » Foundation. It was also partially supported by a grant from the Associazione Italiana Ricerca sul Cancro (AIRC, Milan, No. IG 20100 to MP and MV).
Conflicts of interest
The authors declare that they have no conflict of interest.
Consent for publication
This publication has been approved by all co-authors.
S. Luigi Hospital, Orbassano (Turin) Ethical Committee #610, date December 20th, 2017.
All participants provided written informed consent before inclusion.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Roberta, P., Maria, S., Enrico, G. et al. Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations. Endocrine (2020). https://doi.org/10.1007/s12020-020-02438-7
- Struma ovarii
- RAS mutation
- BRAF mutation
- Thyroid cancer
- Next-generation sequencing